Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the ...

Gilead Sciences recently experienced a significant ... highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.

New PURPOSE 1 Data Showcasing Preference for Twice-Yearly Lenacapavir vs. Once-Daily Orals and In-Depth Look at Adolescent Pharmacokinetic, Safety and Efficacy Data – Gilead Sciences ...

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...

Gilead Sciences, Inc. (NASDAQ ... announced promising Phase 1 study results for two once-yearly formulations of lenacapavir, an investigational drug for HIV prevention, at the Conference on ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and ...